publication date: Jun. 6, 2014

CHICAGO—The consequences of diminishing federal support for cancer research can be measured in the abstracts presented at the 50th annual meeting of the American Society of Clinical Oncology that concluded earlier this week.

To illustrate the impact of this drought, ASCO developed a graphic label to identify abstracts stemming from studies that had received U.S. federal funds.

Altogether, 169 abstracts were identified in this manner at the annual meeting. By way of comparison, 575 studies received federal funding in 2008.

“We are already seeing a real—and we think, disturbing—bit of evidence of the impact of the reduction in federal support,” said Clifford Hudis, as he was completing his term as ASCO president. “This is the predictable end result of the steady decline in federal support of clinical cancer research in the US.”

Being primarily a clinical society, ASCO focuses on studies that have the potential to improve patient care.

“The fact that all four of the plenary sessions abstracts that you will hear about received federal funding demonstrates the important role that this source plays in supporting critically important, clinically relevant research,” Hudis, chief of the Breast Cancer Medicine Service and an attending physician at Memorial Sloan-Kettering Cancer Center, … Continue reading 40-23 NCI-Funded Clinical Research In Jeopardy, ASCO Focuses on Value of NCTN Groups

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.